-
admin
Posts
State Grid Changzhou Power Supply Company Develops Low-Voltage Generator Vehicle to Ensure Uninterrupted Power Supply
CHANGZHOU, China, Aug. 10, 2024 /PRNewswire/ — “Voltage and current outputs of the generator vehicle are normal, ensuring steady power supply to the low-voltage district!”...
2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) Singapore Division Finals to Begin Soon
Smart Binhai, Glorious Competition! SINGAPORE, Aug. 10, 2024 /PRNewswire/ — With the success of the Hong Kong SAR Final Round of the 2024 China Tianjin Binhai...
11,000 Global Financial Insurance Elites Converge in Kuala Lumpur. International Dragon Award IDA members share glorious moments
A grand celebration of insurance knowledge and honor, united in wisdom and glory. KUALA LUMPUR, Malaysia, Aug. 10, 2024 /PRNewswire/ — The 15th Worldwide Chinese...
Shareholder Rights Attorneys Robbins LLP Alerts ODD Stockholders of the Class Action Against Oddity Tech Ltd.
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities...
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research,...
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related...
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the...
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry...
Momcozy Introduces the Ergonest Maternity Belly Band: the Best Belly Band for Summer
New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) — Momcozy introduces the Ergonest Maternity Belly Band, designed to provide targeted relief and exceptional comfort for expectant...